Search results
How B cells recognize new variants of SARS-CoV-2
Medical Xpress· 3 days agoThe team describes how this works in the European Journal of Immunology. During the corona pandemic, the vaccination against SARS...
Man Dies After Having COVID for 613 Days
People Magazine· 7 days agoPer...Center (Amsterdam UMC) in the Netherlands released on April 18, the man had "the longest SARS-CoV-2 [COVID-19] infection duration ...
Optimal timing maximizes Paxlovid benefits for treating COVID-19
Medical Xpress· 3 days agoResearchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published ...
Dozens of COVID virus mutations arose in man with longest known case, research finds
Medical Xpress· 7 days agoWorse, several of the mutations were in the COVID spike protein, indicating that the virus had...
Data: Optimal initiation of Paxlovid in hospitalized COVID patients is 3 to 5 days
Center for Infectious Disease Research and Policy· 2 days agoTaking the SARS-CoV-2 antiviral drug nirmatrelvir-ritonavir (Paxlovid) 3 to 5 days after COVID-19...
72-year-old patient had COVID for record 613 days, accumulated over 50 mutations from virus before...
NY Post via Yahoo News· 7 days ago“We emphasize the importance of continuing genomic surveillance of SARS-CoV-2 evolution in...
Are Monoclonal Antibodies the Future of Long COVID Treatments?
Technology Networks· 3 days agoOne study published in PLOS Pathogens in 2022 found that long COVID patients had 100 times the...
COVID-19 virus disrupts protein production: Researcher discusses her recent findings
Phys.org· 2 days agoOne thing we do know: Following infection, it's critical that our cells make new proteins to defend against the virus. Writer Jenni Bozec recently spoke with Yerlici—who is ...
Immunologist receives biomedical research award | Cornell Chronicle
Cornell News Service· 1 day agoAshley Nelson, assistant professor of immunology research in the Department of Pediatrics at Weill...
Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Livforsakringsbolaget Skandia Omsesidigt
ETF DAILY NEWS· 6 days agoLivforsakringsbolaget Skandia Omsesidigt lifted its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 145.3% in the 4th quarter, Holdings Channel reports. The firm owned 790 shares of the ...